Top biotech licensing deals of Q1 2023
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026
Clinical trial diversity craters out to lowest level in 10 years
Boehringer signals intent in obesity
*please scroll down for all the latest news*
